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ABSTRACT 
Objective: This study was conducted to design a transdermal dosage form of pseudoephedrine HCL and to evaluate its release under controlled 
rates for sustained transdermal delivery of Pseudoephedrine. 
Methods: Transdermal patches were prepared by the casting evaporation method. Utilizing eudragit RL100. Patches were characterized by physical 
appearance, moisture content, thickness, weight variation, folding endurance, tensile strength and stability studies. Fourier transform infrared 
spectroscopic studies (FTIR), differential scanning calorimetry analysis (SCA) and XRD studies. Four different permeation enhancer (Tween 20, 
thymus oil, castor oil and eucalyptus oil) was employed. In vitro release of drugs was done in the dissolution paddle apparatus. Release studies were 
performed in distilled water at 37 °C. Scanning electron microscope studies were performed before and after the drug. 
Results: Transdermal patches with enhancers were formulated successfully with a concentration of 1% (W/V). The patches indicated stable 
physicochemical characteristics. FTIR, SCA and XRD Studies showed that there were no physical and chemical interactions between excipients and 
drugs. Results of in vitro permeation studies showed that enhancers used in this study increased drug released. The enhancers showed faster 
released than no enhancer. This arrangement can be shown as Tween>Eucalyptus oil>Thymus oil and castor oil. Formulation F2 is optimized among 
all formulations showed an 83.3% release.  
Conclusion: Transdermal patches of pseudoephedrine were successfully developed by using pseudo epinephrine HCL. These patches proved to be 
very useful for therapeutic purposes in the pharmaceutical industry without making the patients unconscious, unlike the trivial methods of 
treatment. 
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INTRODUCTION 
Transdermal Drug Delivery Systems are generally known as TDDS. In 
this technique, the drug is normally used in the form of patches. These 
patches are applied on the skin of the patients, which can enter 
conveniently from the skin into the bloodstream, simply by the process 
of diffusion and then transported to their target tissues where they 
display their therapeutic results. These transdermal patches can survive 
in the blood of the patients for a long time, unlike other techniques of 
medications. This system of medication is very effective and 
advantageous; therefore, it has substituted the traditional methods of 
medications and drug application in the field of pharmaceuticals. It is 
patient-compliant, sustainable and avoids damages caused by the liver 
by direct injection of drugs into the body [1]. 
At present, numerous diseases such as motion diseases, 
cardiovascular diseases, and hormonal abnormalities are being 
treated using this technique. The treatment of many other diseases 
like skin cancer, sexual and menstrual dysfunctions in women, 
anxiety, stress, etc. are yet to be treated by using this technique in 
future. The products of the transdermal system generate handsome 
revenue in the international pharmaceutical markets too [2]. 
The application of drugs via trivial methods was very common till 
1990s. This had many side effects like that of gastrointestinal 
ulceration, anemia and liver deformities causing hepatitis. The 
primitive methods of drug administration would most likely cause 
death in certain cases. In order to minimize the risks in the field of 
pharmaceutics, the experts were desperately in need of a technique 
that could overwhelm the side effects of the conventional system of 
medication. They, therefore, introduced the transdermal application 
as an alternate source of treatment, which is simple in applying it 
and patient compliant simultaneously [3]. 
Polymers, enhancers, plasticizers and solvent systems are given due 
consideration while fabricating polymers, which are believed to be 
the key ingredients of the transdermal drug delivery system because 
the frequency of drug penetration and its release depends upon 
polymers. Pseudoephedrine hcl is a sympathomimetic drug of the 
phenethylamine and amphetamine chemical classes. It may be used 
as a nasal/sinus decongestant and as a stimulant, or as a 
wakefulness-promoting agent in higher and frequent doses, 
therefore, to avoid the systemic circulation, so as to overcome the 
hazardous effects of oral applications of drugs [4]. 
Pseudoephedrine HCl a short half-life of 4-5 h. Doses of 20 mg are, 
therefore administered orally 3 to 4 times a day [5]. However, 
frequent dosing may cause side effects, including tachycardia, 
hypotension, insomnia, and tremors. The objective of this study was 
to formulate a pseudoephedrine HCL patch for transdermal 
administration. 
MATERIALS AND METHODS 
Chemicals 
Pseudoephedrine HCl (SS) was fetched as a gift sample from Merck 
(Quetta, Pakistan). Eudragit RL 100 and Polyvinyl alcohol that had a 
Molecular Weight of 72 000 were procured from Sigma-Aldrich, UK. 
Thymol oil extracted in the lab of UOB. Eucalyptus oil was fetched 
from George Rennie, France. Tween 20 and Methanol bought from 
Merck, Germany. Distilled water was obtained from the assembly of 
water distillation. This facility was available at the laboratory, 
Faculty of Pharmacy and health services, University of Baluchistan, 
Quetta, Pakistan. 
Backing membrane preparation 
Polyvinyl alcohol (PVA) was utilized for the purpose of making the 
backing membrane of patches. A conical flask was taken in order to 
prepare a solution (Aqueous 4% w/v) of PVA. During this process 
stirring in flask continued with hot plate stirrer by keeping Temp at 
Eighty Degrees Centigrade. Cooling of the solution was done, 
followed by a deaeration of PVA solution in a sonicator for two 
minutes. Lastly, a glass petri dish (61 cm2) was taken in which 
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fifteen mili liter ml prepared solution was transferred that had dry 
air for twenty-four hours [6]. Films were dehydrated at room 
temperature. Furthermore, for the purpose of fabricating 
transdermal patches; the conditions of the laboratory, particularly 
that of temperature and humidity, were kept favorable (i.e. 25 ° and 
75% RH). A series of membranes were prepared keeping conditions, 
ambient wherein air-drying of PVA films were applied in this case. It 
was proposed by Raruf et al. that the films, in which Chitosan was 
blended, had wonderful physical and chemical properties [7]. 
A waterproof PVA membrane secures the transdermal system from 
that of the hazards of the outside environment. The process of 
permeation of drugs via skin [8]. In enhanced because of the 
obstructive nature of PVA membrane. For the purpose of making of 
baking membrane, PVA is the commonly used polymer [9, 10]. 
Preparation of the casting and matrix solution 
Variables of formulation/100 ml of matrix dispersion are shown in 
table 1. A conical flask (250 ml volume) was taken to prepare the 
solution of patch formulation. For this purpose, 100 mili liter of 
methanol and 5 g eudragit was added in the conical flask (250 ml 
volume). 500 rpm magnetic stirrer was used in which the sealed 
conical flask was stirred for thirty minutes. The solution was mixed 
completed after that, enhances and related plasticizer was also 
added, which was further mixed for half an hour. In order to get a 
standardized dispersion, pseudoephedrine HCl (0.620 g) was added 
and then also stirred for half an hour. The aforesaid amount of PE is 
further added in 100 ml of solvent to get 1.5 mg of PE for every 
patch that has a size of 1.5 cm2. In order to eliminate the entrapped 
air, matrix dispersion was sonicated for a further five minutes. The 
Petri dishes that had PVA backing membrane were taken in which 
10 ml of the aforementioned matrix was emptied, which were put 
horizontally for a period of twenty-four hours at room temperature. 
In order to avoid quick evaporation of the solvent, the petri dishes in 
this process were covered using inverted funnels. The patches, 
containing, antiasthmatic drugs, were dried first and later on 
detached from Petri dishes cautiously. The patches were then 
enfolded into aluminum foil and stirred further at 25°. 
 
Table 1: Formulation variables of transdermal patches 
Ingredients F1 F2 F3 F4 F5 
Eudragit RL 100 (g) 5 5 5 5 5 
Castor oil(g) 5 - - - - 
Tween 20 (g) - 5 - - - 
Eucalyptus oil (g) - - 5 - - 
Thymus oil (g) - - - 5 - 
Methanol (ml) 100 100 100 100 100 
 
Patches cuttings 
A stainless steel cutter (1.5 cm2) was used to cut films. The cuts were 
circular in shape.  
Transdermal patches and their physical evaluation 
Different physical characteristics of patches were assessed. 
Properties like smoothness, brittleness and clarity were visually 
evaluated [11]. From every formulation, 3 patches were randomly 
taken. An analytical balance (Shimadzu AUX220, Germany) was used 
to measure uniformity in weight, weight variations of those circular 
patches. Measurement of thickness was done with an electronic 
micrometer screw gauge (Sharp fine Type-A, China). Thickness of 
the circle cut patches was measured three times. Then the mean 
value was opted as standard. 
A manual test was done so as to determine the strength and folding 
endurance of circularly cut patches by selecting 3 patches for 
checking the above-mentioned capacity of patches. Finally, averaged 
of these 3 trials was taken [12]. 
The property of moisture uptake, integrity and stability of 
transdermal patches was also assessed. For this purpose, a humid 
condition was opted to use a saturated solution of KCl and circularly 
cut (1.5 cm2) patches were weighed first. Secondly, a desiccator was 
used to put a film in it at room temperature. The patches were 
regularly weighed till getting a constant weight. The formula given 





FTIR spectroscopy analysis 
The compatibility study was done with Fourier Transform Infra-Red 
spectroscopy (FTIR) on prepared transdermal patches in the 
presence and absence of pseudoephedrine HCl, respectively. A 
sample holder (Attenuated Total Reflectance (ATR) Bruker FTIR; 
Tensor 27 series, Germany) was taken in which sample was put. 
Sample analysis was done with a software (Opus data collection 
software), with 4000–750 cm−1 wavenumber [14]. 
Microscopy through scanning electron microscopes 
SEM was done with an electron microscope (Quanta 250), that had 
software (Hillsboro, Oregon, USA) [15]. 
X-ray diffraction (XRD)  
For the confirming nature of drug matrix film (i.e., to determine 
whether it is amorphous or crystalline), X-ray diffraction studies of 
the drug (PE.), matrix (PE.) were conducted with software PAN 
analytical (Netherlands). An anode made of Cu-Ka (30 KV and 15 KA 
current) was used for determining measurement. Then the 
diffractograms were captured at a rate of 2 min while keeping the 
temperature at ambient. A step width of 0.02 °and 2Ф between the 2° 
and that of 60° was used for this purpose [16]. 
Drug content 
This was followed by (Gul et al., Gupta et al. and Dandagi et al.). The 
films (1.5 cm2) from every formulations-in the presence and absence 
of drug-were cut into small pieces that were placed in a conical flask 
of one hundred mili liter of H2 O. The Flask was placed on a magnetic 
stirrer and was stirred consecutively for thirty-six hours. Later on, 
this solution was put in a sonicator for sonicating in about thirty 
minutes. After sonication for thirty minutes, the solution was also 
filtered. Finally, solutions were evaluated via Spectrophotometer 
(double beam UV/Vis Shimadzu-1601, Germany) by fixing its 
wavelength at 210 nanometers for PE [17]. 
In vitro release studies 
A dissolution apparatus (PT-DT7 Pharma Test, Germany) was used 
for this purpose. Patch (1.5 cm2) that had PE (1.5 mg) was put 
horizontally with the help of clips (stainless steel mesh). Water 
was taken as a medium of dissolution by maintaining temp at 
ambient. For checking solubility, five hundred mili liters of 
distilled water were poured in vessels whereas the temp was kept 
at 32±0.5 ° (skin temperature). Paddle blades were placed in such 
a way that the distance between paddles and surface was 25 mm. 
Disk assemblies with patch were put at the bottom of the vessels. 
In vessels, release surfaces were kept in the center and upward 
and were centered with the help of a glass rod. Fifty rpm was set 
as stirring speed while the vessels were shielded to lessen 
evaporation. In order to withdraw five mili liters of release media 
at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20 and 24 h, an 
Autosampler (PTFC II, Pharma Test, Germany) was used. 
Spectrophotometric analysis of drug release was also calculated. 
In order to assess in vitro release, three patches from that of every 
formulation was examined. Finally, the average reading was 
calculated. 
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Stability test  
Stability test was performed by keeping temperature conditions 
different for every formulation made of the plants so as to note 
effects of various temperature conditions for the storage of each 
formulation. Samples were analyzed after 3 mo of storage at 0±1 °C 
(freezer), 8±0.1 °C (refrigerator), 25±0.1 °C (incubator), and 40±0.1 
°C (incubator) [5]. All formulations were tested for changes in 
appearance, drugs contents, moisture contents, and weight 
variations  
RESULTS AND DISCUSSION 
The current study was done with an objective to develop 
transdermal patches of PE drugs possessing that of a matrix type. In 
this regard, a method knows as solvent casting or plate casting 
method was used. Matrix type patches were made by using eudragit 
RL100 as a polymer. Enhancers were also used in this current study 
that comprise of tween 20, castor oil, thymus oil and eucalyptus oil. 
In vitro dissolution and physicochemical properties of different 
enhancers (having various permeability characteristics). 
 
Table 2: Visual appearance of transdermal patches 
Formulation Brittleness Clarity Smoothness Appearance 
F1 X + + Satisfied 
F2 ++ X ++ Satisfied 
F3 ++ ++ ++ Satisfied 
F4 ++ X ++ Satisfied 
F5 ++ + ++ Satisfied 
X=Level of dissatisfaction,+=Level of satisfaction 
 
The patches were visually examined, which demonstrated that 
patches which had tween 20, eucalyptus oil, castor oil and thymus 
oil as permeation enhancers had relatively smooth and clear 
surfaces. Table 2. Properties of permeation enhancers probably 
were the main reason of smoothness table 3. Shows the results of 
the weight variation test, thickness, folding endurance, moisture 
content and tensile strength. The standard deviation having lower 
values demonstrated that the uniforms in terms of weight were 
because of patches that contained antiasthmatic drugs. For the 
purpose of ensuring uniformity in terms thickness of these 
transdermal patches, every patch was assessed at 3 different 
positions by finally measuring the average table 3. Shows the value 
of the thickness of the different patch formulation. The Solvent 
Casting method produced a standard deviation having lower values 
regarding uniforms in terms of thickness in patches. Many 
enhancers were basically applied as a plasticizer and an additive and 
plasticizer for producing transdermal patches. Formulations that 
had tween 20, castor oil, eucalyptus oil and Thymus oil as a source of 
permeability enhancers [18]. Displayed suitable physicomechanical 
characteristics in the absence of plasticizer. 
 
Table 3: Physical properties of pseudoephedrine HCL transdermal patches 
Sample No Weight variations (mg) Thickness (nm) Folding endurance Moisture content (%) Tensile strength 
F1 30.12±0.01 20±0.011 172±1.10 3.1±0.02 0.70±0.01 
F2 29.11±0.32 18±0.021 154±1.01 2.9±0.22 0.57±0.32 
F3 28.12±0.22 22±0.041 164±1.02 3.2±0.12 0.60±0.22 
F4 30.21±0.01 24±0.021 158±1.03 3.4±0.42 0.76±0.02 
F5 29.01±0.01 18±0.011 152±1.01 3.2±0.12 0.71±0.12 
The values are expressed as a mean of three trials,±SD= Standard Deviation 
 
One of the important factors for transdermal patches are polymer 
[19]. The Formulated matrix membrane gets softened and extends 
because of plasticizers, which interpose forces that grip chains of 
polymers while patches have appropriate folding durability; results 
of folding durability and moisture uptake are shown in table 3. 
Lower values of moisture uptake are because of the hydrophobic 
nature of eudragit RL100, which protects the product from 
microbial infection too. The properties of suitable strength and 
elasticity of patches were drawn form tensile strength, which are 
also shown in table 3. 
The difference in terms of uniformity of drug content in different 
patches was not significant, which are shown in table 4. The plate 
casting method used for production of patches, in this study, has 
been proved capable of bringing forth uniformity in the distribution 
of drugs within the patches. 
 






F5  Blank 
The values are expressed as mean±SD= Standard Deviation from the mean, n=3 
 
Fig. 1. Shows the percentage of the cumulative release of both types 
of drugs after a period of twenty-four hours dissolution experiment. 
Drug from that of the F2, which had tween 20 as a permeation 
enhancer, demonstrated the highest percentage of cumulative 
release for both of the drugs. The swift release of drug form those of 
the patches significantly in twenty-four hours are because the 
ammonium group is present in eudragit RL100 which make it 
hydrophilic. The drug is released from that of the polymeric device 
after the formulation mixes with the medium because now the water 
is absorbed by polymer which hydrates and swells patches that 
smoothens drug release. By adding enhancers, the amount of drug 
released fastens via patches during dissolution fig. 1. Which also 
makes the eudragit RL 100 matrix of patches smooth and flexible [20]. 
The films swell because of the penetration of water molecules quickly 
in it, which, resultantly, rises the amount of drug release from [21]. 
Tween 80 has a solubilizing property as well, which causes the highest 
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release of drug from F2. F1 showed the lowest amount of percent 
cumulative PE drug release since permeability enhancer in F1 was 
absent, whereas the formulations that comprised of enhancers 
displayed comparatively higher cumulative release of drugs. 
 
 
Fig. 1: % of drug released from PE Transdermal patches with different enhancers (mean±SD, n=3) 
 
PE was assessed effectively in transdermal patches in the current 
study. Formulated patches possessed reasonable physical and 
chemical properties along with a property of uniformity of drug 
dispersion. Different permeation enhancers were added in order to 
optimize the rate of In vitro release and ex vivo permeation. F2, that 
had tween 20 as an enhancer, was the best in terms of performance. 
F2 demonstrated drug release in large quantity via patches. The 
results of stability studies were also positive. The patches in which 
enhancers were not added showed poor permeability. The results of 
this study offer an inclusive information to developing and 
optimizing transdermal patches of PE. HCl drugs by using different 
chemical enhancers. 
FTIR spectroscopic analysis 
For the purpose of finding out any physicochemical interactions 
between the polymers, drugs and blends of prepared patches, FTIR 
spectroscopy was done for PE in [fig. 2a]. Ammonio Methacrylate 
Copolymer Ph Eur RL 100, as shown in fig. 2. The FTIR spectra of pure 
PE had characteristic peaks at 3,369 cm1 and 3,288 cm1 
corresponding to NH stretching, 1,707 cm1 and 1,674 cm1 due to 
carbonyl stretching, 1,345 cm1 describing CN stretching, and these 
characteristic peaks of PE were also found in prepared patches of 
polymeric blends. The results obtained from FTIR spectroscopic 
analysis proved that no chemical incompatibility between GPE and the 








Fig. 2: FTIR spectra of (a) Pseudoephedrine hcl, (b) Blank patch (c) physical mixture of polymers plus drug 
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Drug, with its morphology, was studied under an electron 
microscope after the drug was released. Gapes having irregular 
shapes were observed under an electron microscope because the 
polymer used was water-soluble in nature. SEM results showed that 
the drug indeed had elasticity in its nature because the films did not 





Fig. 3:(a) Illustrates surface morphology of the polymeric films before the drug release, while (b–c) display surface morphology of 
polymeric patches after the drug release at different magnification powers 
 
XRD studies 
X-ray diffraction studies were applied to confirm the physical and 
chemical properties of PE and polymeric matrix of patches. Pure PE 
showed sharp peaks of diffraction at an angle of the 2θ value of 
13.52 °, 18.23 °, and 21.18 °, etc. X-ray diffractograms are shown in 
[fig. 4 a]. That shows the crystalline nature of PE, which was 
reported by Mokale et al. previously. PE and Ammonio Methacrylate 
Copolymer Ph Eur RL, displayed peaks having lesser intensity, while 
in diffractograms of the PE patch, fused peaks were present. 
 Irregular peaks of PE demonstrated that drug changed into an 
amorphous type in polymeric films with a molecularly discrete 
nature. 
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Fig. 4: X-ray diffractograms of (a) Pseudoephedrine pure (b) loaded Pseudoephedrine hcl polymeric patches, and (c) Blank patch 
 
CONCLUSION 
Pseudoephedrine transdermal patches were successfully formulated 
with a high in vitro release rate. Tween 20, Eucalyptus oil, castor oil 
and Thyme oil effectively enhanced of pseudoephedrine. Using 
Pseudoephedrine HCL type of transdermal patches is very useful for 
therapeutic purposes in the pharmaceutical industry. Further 
studies are necessary to evaluate the efficacy of the 
pseudoephedrine patches in vivo  
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